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Abstract Using a pilot trial design in an HIV care clinic
in Zimbabwe, we randomised 32 adults with poor adher-
ence to antiretroviral therapy and at least mild depression
to either six sessions of Problem-Solving Therapy for
adherence and depression (PST-AD) delivered by an
adherence counsellor, or to Enhanced Usual Care (Con-
trol). Acceptability of PST-AD was high, as indicated by
frequency of session attendance and through qualitative
analyses of exit interviews. Fidelity was[80% for the first
two sessions of PST-AD but fidelity to the adherence
component of PST-AD dropped by session 4. Contamina-
tion occurred, in that seven patients in the control arm
received one or two PST-AD sessions before follow-up
assessment. Routine health records proved unreliable for
measuring HIV viral load at follow-up. Barriers to mea-
suring adherence electronically included device failure and
participant perception of being helped by the research
device. The study was not powered to detect clinical dif-
ferences, however, promising change at 6-months follow-
up was seen in electronic adherence, viral load suppression
(PST-AD arm 9/12 suppressed; control arm 4/8 sup-
pressed) and depression (Patient Health Questionnaire—
4.7 points in PST-AD arm vs. control, adjusted p
value = 0.01). Results inform and justify a future ran-
domised controlled trial of task-shifted PST-AD.
Keywords Adherence  Depression  Sub-Saharan Africa 
Problem solving  Intervention
Introduction
HIV remains one of the biggest challenges facing sub-Sa-
haran Africa (SSA), with 25.5 million people estimated to be
infected in 2015, 1.4 million new infections, and 72% of
global HIV-related deaths [1]. In Zimbabwe, there are 1.4
million people living with HIV (PLWH), which is 14.7% of
the adult population [2]. Among PLWH aged 15–64 who
know their status, 86.4% self-report current use of
antiretroviral therapy [3]. For those who have tested HIV-
positive, the global target for 2020 is to have 90% on ART
and for 90% of those to be virally suppressed [4]. It is esti-
mated that ART adherence levels of 80–95% are required in
order for individuals to achieve viral suppression [5].
As confirmed through systematic reviews [6], psycho-
logical interventions that emphasise motivational and
problem-solving approaches have in some settings been
shown to enhance ART adherence and/or viral suppression
in treatment-experienced patients [7, 8]. However, such
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approaches are rarely available in low-income countries,
due in part to the lack of behavioural medicine specialists.
There is thus much merit in research on psychological and
behavioural interventions, which could potentially be
delivered by non-specialists through task-sharing. We have
described elsewhere qualitative research to learn about
barriers to adherence in Zimbabwe [9]. We have also
described use of those data to inform adaptation of Life-
Steps [10], a structured adherence intervention with edu-
cational, motivational and problem-solving components.
Modifications were made in terms of language, session
length, tailoring of content for delivery by lay counsellors,
and inclusion of culturally competent probes [11]. We
called the culturally adapted psychological intervention for
adherence Nzira Itsva, which translates as New Direction.
In SSA, as is the case world-wide, depression is one of
the key predictors of poor adherence to ART [12]. Even in
mild form, depression is associated with a 42% lower
likelihood of achieving good adherence to ART compared
to those without depressive symptoms (pooled OR = 0.58,
95% CI 0.55–0.62) [13]. This is important for two reasons.
First, significant depression symptoms are found in up to
half of all people living with HIV [14]. Second, the char-
acteristic symptoms and impairments found in depression
are likely to interfere with critical functions necessary to
maintain good adherence, such as information processing,
planning, problem-solving, and activation of adherence
behaviours [15, 16]. Classical symptoms and impairments
found in depression include repetitive negative thinking,
poor attention, persistently low mood, slowed cognition,
and diminished executive functioning [17–19]. Poor
adherence to ART is likely to be the mechanism by which
depressive symptoms predict higher rates of progression to
AIDS and worse survival for PLWH [20], although
depression may also have a direct effect on immune status
[21].
Despite the strong link between depression and poor
adherence, and evidence that psychological and pharma-
cological treatments improve depressive symptoms and
general function for PLWH with depression, it is striking
that treatment for depression is mostly absent in HIV
facilities in low-income settings. A key reason for this is
the lack of mental health specialists and of culturally-
adapted therapies. In SSA, the median number of mental
health professionals (1.7 per 100,000 population [22]) is
less than one fiftieth the rate in the United States (92.7
mental health professionals per 100,000 population [23]).
Zimbabwe, with a 13 million population, has only two
clinical psychologists and 10 psychiatrists in government
service. As is common in low-income countries, antide-
pressant drugs are also in limited supply, and most staff in
general health care settings are not trained to prescribe
them.
In four trials in the US, Cognitive-Behavioural Therapy
(CBT) for depression was integrated with a multi-component
cognitive-behavioural adherence intervention. Benefits were
seen for adherence and/or viral suppression as well as for
depression [24–27]. There is only weak evidence that treat-
ment of depression alone without additional adherence
counselling improves adherence to ART [28]. Also a large
randomised controlled trial of antidepressant therapy foundno
significant effect on adherence, despite good benefit for
depression [29]. To date, there have been no randomised trials
of psychological interventions for depression and adherence
in low income countries. Our intervention combines Problem-
Solving Therapy (PST) for depression, locally known as
‘Opening Up the Mind’ or Kuvhura Pfungwa [30, 31], with
Nzira Itsva for adherence. In the local setting we named the
integrated treatment for depression and adherence ‘TENDAI’
(meaning ‘thankful’ in the Shona language). Problem-Solving
Therapy is a brief evidence-based intervention derived from
social problem-solving, in which patients are taught a struc-
tured approach to identify problems and find workable solu-
tions [32]. It is an attractive option for low-resource settings,
because unlike CBT, it does not require extensive training or
complex skills [33]. We have further embedded PST in a
stepped care model, both to maximize efficiency of resource
allocation [34] and to incorporate principles to guide treat-
ment choices [35].
The aims of this feasibility study were to measure
acceptability of the PST-AD intervention for participants
and for clinic staff; test methods that would inform a future
randomised trial; and gather data to inform a sample size
calculation for a future trial.
Methods
Setting
We recruited participants over 14 weeks (September–
November 2014, January 2015) at the Parirenyatwa Hospital
Family Care Centre (PHFCC), a government clinic affiliated
with the University of Zimbabwe College of Health Sciences
(UZCHS). This clinic provides comprehensive HIV care for
around 3000 adults and 1000 children onART. Patients attend
an average of 12 appointments annually. Registered patients
receive clinical reviews, ART, HIV-related opportunistic
infection prophylaxis, CD4T cell profile and annual viral load
tests at no cost, but are required to pay for additional labora-
tory and diagnostic evaluations. Patient clinical data is entered
on an electronic medical record as well as hand written into a
notebook that is retained by the patient and serves as their
personal, mobile health record. Medical doctors provide the
bulk of the primary care, with nurses having limited pre-
scribing capability. Patients suspected of having a mental
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disorder could be referred to the psychiatry clinic in a separate
building, although in practice only about six referrals were
being made per month with no records of the outcome.
Study Design
The design was an individualised randomised controlled
trial in which an experimental intervention was compared
to enhanced usual care (EUC). All participants in the
experimental arm had experienced usual care when they
initiated ART, and all counsellors trained in the experi-
mental treatment had previously used usual care. There-
fore, both patients and counsellors had previous experience
of usual care to compare with.
Study outcomes are summarised in Table 1.
Recruitment
Recruitment was conducted through an announcement by
the trained research assistant (RA) asking for volunteers
while patients waited for their clinical evaluations or lab-
oratory tests, and through medical staff directly referring
patients who were considered at risk of poor adherence. If a
patient was interested, they were screened by the RA in a
confidential space. The following inclusion criteria were
used: aged 18 or over; on ART for at least 4 months; and
risk of poor adherence as indicated by any one of the fol-
lowing: (i) missed at least one clinic appointment in the last
3 months; (ii) falling CD4 count or detectable viral load in
the previous 6 months; or (iii) self-report of poor adher-
ence (admitting to having missed one or more doses, taking
treatment late, or being forgetful with treatment). Those
meeting criteria were interviewed and to be included had to
(iv) screen positive for at least mild depression, as defined
by scoring at least 5 on the Patient Health Questionnaire,
and/or at least 9 on the Shona Symptom Questionnaire.
Depression Measures
We screened for depression using the Patient Health
Questionnaire (PHQ-9). The PHQ-9 asks about symptoms
over the past 2 weeks, deriving its scoring system from the
DSM-IV criteria for depressive disorders. Each of the nine
items is scored from 0 (not at all) to 3 (nearly every day). It
is used as a continuous score ranging from 0 (no depressive
symptoms) to 27 (all symptoms occurring daily); as a
Table 1 Study Outcomes
Aim Outcome
Feasibility of methods for conducting a trial in this setting Recruitment: Proportion of screened participants eligible to take part,
proportion of eligible participants consenting, time taken to recruit
Trial retention: Proportion of participants able to be followed up at 4 months
Feasibility of using routine clinic data: Monitor missed appointments, CD4
and viral load, as measured by proportion of data gathered.
Feasibility of using the Wisepill device to measure electronic adherence:
Number of measurements recorded; participants’ experiences of using the
device
Acceptability of the intervention for participants and clinic staff Proportion of sessions attended, proportion of sessions where non-specialist
collected depression measure
Number of weeks to complete six sessions
Exit interviews with participants and staff
Feasibility of collecting clinical outcome measures at baseline
and at follow-up 6 months after last intervention session
Depression symptom score: Using the Patient Health Questionnaire for
depression and the Shona Symptom Questionnaire for common mental
disorders [36, 37, 59]
Electronic ART adherence score: Measured by the Wisepill device for
14 days at baseline and follow up. The score is the mean percentage of pills
taken on time (±1 h) over the past 14 days. We defined good adherence as
C90% in the past 14 days [60]
Self-report adherence: Based on shortened version of the AIDS Clinical
Trials Group questionnaire [40] to measure any missed ART doses in last
7 days, last 30 days, or last 3 months
Proportion of participants with one or more missed HIV care appointments in
the last 3 months: Derived from the patient record system
Viral load: Detectable viral load[200 copies/ml; mean viral load, derived
from the patient record system
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binary measure, with a cut-point of 10 or greater recom-
mended in the US, (sensitivity and specificity for major
depression of 88%), and as bands, with scores of 5–9,
10–14, 15–19, and 20 plus representing mild, moderate,
moderately severe, and severe depression, respectively
[36]. As a binary measure, the optimal cut-off for PHQ-9 in
Zimbabwe is C11, which provides a sensitivity of 85%
(95% CI 78–90%) and specificity of 69% (95% CI
59–77%) against a SCID diagnosis of depression (Cron-
bach’s a = 0.86) [37]. We also used the Shona Symptom
Questionnaire (SSQ-14). The SSQ-14 was developed in
Zimbabwe, and is an easy to use, binary measure to screen
for depression as well as other common mental disorders,
e.g. anxiety. With the optimal cut-off of C9, the sensitivity
and specificity for the SSQ-14 against a diagnosis of either
depression and/or generalised anxiety is 84% (95% CI
78–89%) and 73% (95% CI 63–81%) respectively. Internal
reliability is high (Cronbach a = 0.74) [37].
At 6-months follow-up, we used both the PHQ-9 and the
SSQ-14. We were interested to use both scales in the fea-
sibility study. The PHQ-9 is known to be sensitive to
change, serves as a screen for depression, and is validated
locally. The SSQ-14 was developed in Zimbabwe, includes
indigenous idioms, and is user-friendly, being a simple
binary questionnaire. It has been validated for depression
and other common mental disorders. If the SSQ-14 does
prove to be sensitive to change, it could be a useful tool
for a future trial given its user-friendliness.
Exclusion Criteria
Patients were excluded if they scored B6 on the Interna-
tional HIV-Dementia Scale [38]; indicated suicidal intent
on the P4 Suicidality Screener [39]; or were assessed by
interviewer to be too unwell, intoxicated, or distressed to
take part. All those meeting study inclusion criteria were
invited to take part.
Randomisation
After giving written informed consent, patients were ran-
domised in a 1:1 ratio to intervention or EUC arms. Ran-
domisation was conducted by participants selecting one
numbered card at random from a bag; each number had
been pre-allocated to either the intervention or EUC arm.
We aimed to recruit 40 participants over 4 months. The
flow of recruitment and randomisation is shown in Fig. 1.
Baseline Assessment
For individuals who met all study criteria and provided
informed consent, the trained RA conducted the baseline
assessment on the day of recruitment. Data collected from
the participant included socio-demographics, ART regimen
and duration of treatment, AUDIT-C screening for alcohol
misuse, and self-reported adherence [40]. Data collected
from the participants’ clinical notebook and/or electronic
records included the two previous viral load and CD4 test
results and any missed HIV care appointments in last
3 months.
Electronic Medication Event Monitoring
Electronic pill bottle monitoring is proven to be a valid
and reliable measure of adherence [41] and can be carried
out with tools such as Wisepill. Wisepill is a
portable medication dispenser that has a cell phone com-
munication chip which sends a signal (medication event)
each time the dispenser is opened. Participants in both
arms were trained to use a Wisepill device and were asked
to store and take their medication from it for 2 weeks prior
to their first therapy session. Adherence records were
available to the clinicians and researcher through a
Wisepill database.
Blinding
Participants were at least partly blinded to their group
allocation as both arms were offered extra sessions of
counselling, which is different from standard care. We
piloted independent assessment of follow-up data on self-
report outcomes of depression and adherence in 25% of
participants, but resources precluded doing this for all
participants. Data on missed appointments, viral load, and
Wisepill adherence at follow-up were collected and anal-
ysed by researchers blinded to study arm.
We collected qualitative data by interviewing a ran-
domly selected sub-sample of 25% of participants (7/28).
Qualitative data were analysed by two researchers outside
the core research team who were not aware of the content
of sessions in the intervention or EUC arms. The two
researchers were trained in qualitative data analysis and
had a background in mental health in low-income countries
(see acknowledgements).
Fidelity to the Intervention
The supervising psychologist and a research psychologist
independently rated fidelity in a random 15% of recordings
(24 sessions) using a therapist checklist adapted from one
used for similar interventions [24]. Six evaluations were
conducted each of a session 1, 2, 3 and 4 of the interven-
tion. Sessions were rated on the presence or absence of key
competencies for each session, for instance setting an
agenda, reviewing adherence in the past week, or review-
ing progress on the solution generated in the previous
AIDS Behav
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Problem-Solving Therapy for Adherence and Depression Enhanced Usual Care
Above cut point Below cut point
Above cut point Below cut point
Session 1
Adherence counselling 
usual care
Session 1
PST for adherence
Session 2
PST for depression
Adherence booster
Session 3
PST for depression
Evaluate progress and 
generate new soluons
Adherence booster 
Session 4
PST for depression
Evaluate progress and 
generate new soluons
Adherence booster
Repeat SSQ-14 assessment
Session 5
Connue PST for 
depression with 
ART counsellor
Session 5
Step-up to 
psychologist joint 
session
PST for depression
M
O
N
TH 
Session 2
Adherence counselling 
usual care
M
O
N
TH 2
Session 3
Adherence counselling 
usual care
M
O
N
TH 3
Treatment CompleteReferral to psychiatrist for 
assessment +- andepressant 
treatment
Session 6
Psychologist joint 
session
PST for depression
Repeat SSQ-14 
assessment
Session 6
Connue PST for 
depression with 
ART counsellor
Repeat SSQ-14 
assessment 
Fig. 1 Flow-chart showing the experimental and enhanced usual care interventions
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session. Competencies covered both the depression and the
adherence component of the intervention.
Fidelity ratings were carried out 3 months after the
study had ended. Disagreements were resolved by discus-
sion and consensus through a 3-way face-to-face discussion
with the first author.
Follow-Up
Participants were followed up at 6 months on both mea-
sures of depression and adherence, using the same mea-
surement tools as at recruitment. Follow-up took place in
the respective clinic, however if the patient was unavail-
able or did not arrive for follow-up, they were contacted
and assessed by telephone.
Experimental Intervention
Problem-Solving Therapy for Depression and HIV
Medication Adherence (PST-AD)
The intervention, locally named the TENDAI intervention,
is delivered over 6 weekly sessions: the first two sessions
50 min; sessions 3–6 30 min. Session 1 is Nzira Itsva, the
culturally and linguistically adapted Life-Steps adherence
intervention [10, 42]. As described elsewhere [11], Nzira
Itsva has a series of motivational, informational, problem-
solving and behavioural steps. In the local context, we had
found that clients commonly responded by wanting to work
on generating solutions to barriers to getting to appoint-
ments (such as very constrained finances or lack of
autonomy at work or home to attend the clinic), asking
questions of the medical team, having a regular pill-taking
schedule (which was especially hard where the person had
not disclosed their status in the household) and, for women,
dealing with ways in which their husband might be inter-
fering with pill-taking. This first session is operationalized
with detailed daily adherence data over the past 2 weeks
generated by the Wisepill electronic device.
Session 2–6 follow classical PST for depression including
psycho-education about depression; eliciting, listing and
reflecting back to the participant their problems; helping
them to select one problem from the list to focus on; brain-
storming solutions; rating them according to importance and
feasibility; choosing a solution; and making a plan to
implement it over the next week [43]. Subsequent sessions
include evaluating progress andmay include generating new
solutions and tackling different problems. The counsellors
were trained to include 10–15 min on adherence barriers in
session 2–6, building on the first session, checking progress,
and using the PST approach to try to find solutions for
additional barriers. The counsellor met weekly with the
psychologist to discuss her case-load.
Stepped Care
At session 4, the counsellor repeated the SSQ-14 screening
scale for depression. If the SSQ-14 score remained above
8/14 and/or the patient was having difficulty generating
solutions to problems, the ADC had the option to step up
the intervention. This involved asking the psychologist to
see the client in session 5 as a joint session. The psychol-
ogist could advise the counsellor and/or deliver Session 6
also as a joint session.
The ADC repeated the SSQ-14 assessment at Session 6
for those she suspected were not improved. Those scoring
above the cut-off point could be discussed again with the
psychologist or referred to a psychiatrist for an assessment
for antidepressant treatment (Step 3 of the intervention).
Although we had considered using antidepressants, such as
Fluoxetine, for Step 2 care, we found they were not
available in the general healthcare pharmacy in the HIV
clinic, and were poorly available more generally in Zim-
babwe. Also, the medical staff in the HIV clinic were
neither willing nor confident to prescribe these drugs.
There were additional concerns about pill burden, possible
interactions with antiretroviral therapy, and lack of desir-
ability of using Tricyclic Antidepressants, which would be
the most available option. We thus focused on psycho-
logical therapy for Step 2. Although the emphasis remained
on problem-solving therapy, at Step 2 it was provided by
someone more qualified than the adherence counsellor.
One Adherence Counsellor (ADC) trained in PST-AD
delivered the intervention for all the participants in the
PST-AD arm. Although we had trained three others in
PST-AD, one of these emigrated, and two ADCs were
moved to different departments within the clinic, as they
were perceived by the matron to have new skills which
could be deployed in critical clinical areas.
Control Intervention
Usual Care Counselling for Adherence to ART
Counselling is provided by ADCs. This cadre are usually
primary care counsellors or nurse aides who have sec-
ondary school education and 6 months of training in HIV/
AIDS basic counselling. Counselling sessions include
information about HIV/AIDS, safe sex practices, diet,
keeping a positive attitude towards living with HIV, and
why ART is important. Advice is given on how to take
medication and any social problems that emerge during the
discussion. Counselling is routinely provided under four
conditions: (1) when a patient initiates ART; (2) when a
patient has ‘defaulted’ from their treatment i.e. did not
collect medication for some months, or (3) when a patient
is clinically suspected of poor adherence through having a
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falling CD4 count or high viral load, or (4) admits to poor
adherence through self-reported difficulty in compliance.
Those initiating ART or those who ‘default’ treatment
attend one group-based and one individual session of ART
counselling. Those considered at risk of poor adherence are
referred for one individual session, although depending on
need, as perceived by the counsellor or clinician, that could
in rare cases be repeated.
Enhanced Usual Care (EUC)
Four ADCs who had not been trained in the PST-AD
intervention delivered the EUC. We enhanced usual care
by (1) increasing usual care from one session only, to one
session a month for 3 months, and (2) ensuring continuity
of the same counsellor for all sessions. ADCs providing
EUC were asked to repeat the information they normally
provide. They were not trained in the local version of Life-
Steps.
Data Analysis
Study data were collected and managed using REDCap
electronic data capture tools hosted at the University of
Zimbabwe, College of Health Sciences [44]. All analysis
was undertaken using Stata (V.14). Binary outcomes were
analysed using Fisher’s exact test due to small numbers. To
analyse the continuous depression and adherence outcomes
by arm, linear regression models were used, adjusting for
baseline outcome score. An intention to treat analysis was
then performed to include every subject who was ran-
domized according to randomized treatment assignment.
Intention to treat analysis reflects the real-world clinical
scenario because it admits noncompliance and protocol
deviations [45]. It thus minimizes type I error due to a
cautious approach and allows for the greatest generaliz-
ability [46].
Semi-structured interviews were coded and analysed in
NVivo10 using grounded theory principles [47] and the-
matic content analysis [48]. For each interview, we created
a list of conceptual components (‘opening coding’) and re-
categorised these ideas into initial themes based upon the
study objectives of investigating the acceptability and
potential benefits of the PST-AD intervention [49]. Initial
themes were adapted into a framework through a process of
iteration, and additional themes were added as determined
by the data.
Ethics
The study was approved by the Medical Research Council
of Zimbabwe and the Research Council of Zimbabwe
(MRCZ/A/1736), the Joint Parirenyatwa Hospital and
College of Health Sciences Research Ethics Committee
(JREC 18/13), and King’s College London College
Research Ethics Committee (PNM/13/14-158). The trial
was also registered with the Pan African Clinical Trials
Registry (PACTR201511001150307).
All participants provided informed consent. Participants
were compensated with USD3 per visit for public transport
costs and were provided with refreshments.
Results
Recruitment
Over 14 weeks, clinic doctors referred 94 patients with a
detectable viral load, of whom 79/94 (84%) were willing to
be screened. We screened a further 13 who volunteered
among those waiting in the blood test queues as having a
high viral load and/or having problems with adherence. As
shown in Fig. 2, 44/99 (47.8%) scored at or above the cut-
point for depression on the PHQ-9 and/or on the SSQ-14,
of whom four were excluded as they later proved not to
have any of the clinical criteria for poor adherence to ART.
Five patients were excluded due to being severely dis-
tressed and/or suicidal. Only three declined to take part,
two citing distance from the clinic as a barrier to attending
counselling sessions and one saying he was busy with
exams. As shown in Fig. 2, 14 patients were randomised to
the intervention arm and 18 to the control condition, and 28
completed follow-up. As shown in Table 2, those in the
intervention arm did not differ in terms of gender (65%
female) or marital status, but were less likely to be
employed or to have tertiary education than those in the
control arm.
Attendance and Session Completion
For those randomised to the 6-session intervention, the
mean number of sessions attended was 5.2 (SD 1.6). Ten of
the 14 participants (71%) completed all six sessions, 2
(14%) completed five sessions, and two (14%) completed
one or two sessions. For those who completed six sessions,
the median duration from first to last session was 8 weeks.
For those randomised to the 3-session EUC, the mean
number of sessions was 2.4 (SD = 0.6). For 20% of par-
ticipants, the research assistant made more than one phone
call to re-book their next session.
Follow-Up at 6 Months
Trial retention was 88% (28/32,) with 13 intervention
participants (93%) and 15 control participants (83%) fol-
lowed up. Two follow-up interviews were conducted by
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telephone. The four participants lost to follow-up did not
appear to differ significantly from the remaining 28
patients in their baseline characteristics of gender, age or
marital status.
Fidelity to the Intervention
Fidelity to sessions 1 and 2 was high (83 and 88%
respectively) out of 10 competencies each. For sessions 3
and 4, fidelity dropped to 63 and 53% respectively. This
was almost entirely due to the drop in fidelity to the
adherence component of sessions, which was only 33%.
The main gaps were that the counsellor commonly omitted
to review adherence in the past week, or to review addi-
tional adherence barriers or work with the client to develop
ways to overcome them. For sessions 3 and 4, fidelity was
75% for the competencies for PST for depression.
Feasibility of Measuring Clinical Outcomes
(Table 3)
Depression Scale Scores
We were able to collect data on depression for all partic-
ipants at baseline and for 28/32 (87.5%) at follow-up (two
participants provided follow-up interviews by phone). The
Adherence Counsellor was able to measure depression at
session 4 for 100% of participants in the PST-AD arm.
Being in the intervention arm compared to the EUC arm
was associated with 4.7 points lower PHQ-9 score at fol-
low-up (95% CI -8.2, -1.3 p = 0.010) controlling for
baseline PHQ-9 score (N = 28, 25 residual degrees of
freedom, F = 3.95, adjusted R2 = 18%) (Table 3). The
participants in the intervention arm also had 1.13 points
lower mean SSQ-14 score at follow-up (95% CI -3.25,
0.99) as compared to the EUC arm, after adjusting for the
effect of baseline SSQ-14 score, but the effect was not
significant (p = 0.284, N = 28, 25 residual degrees of
freedom, F = 5.55, adjusted R2 = 25%). In terms of
clinical significance, in the intervention arm, the average
depression score on the PHQ-9 fell from ‘moderate
depression’ range to ‘no depression’ range. In the EUC
arm, average depression score on the PHQ-9 also fell, but
remained in the ‘mild depression’ range at follow-up. Only
one of the 13 intervention participants (8%) but 6 of the 15
EUC participants (40%) were still above the cut-off for
depression on either the PHQ-9 or the SSQ-14.
Missed HIV Care Appointments
It proved feasible to measure missed appointments through
the clinic record system. At baseline a similar proportion in
Number eligible but declined to take part: 3
15 completed follow-up
Number randomised: 32
Number excluded: 57
Depression score below cut-point: 48
Self-report poor adherence or viral load 
results inconsistent: 4
Too distressed and/or suicidal: 5
Paents at risk of poor adherence screened: 92
Intervenon: 14 Enhanced usual care: 18
18 completed baseline
13 completed follow-up
14 completed baseline
Fig. 2 Flow-chart showing the
progress of participants from
screening to follow-up
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the EUC arm (22%) and in the PST arm (29%) had missed
appointments in the previous 3 months. However, at follow
up, a greater proportion in the EUC arm (44%) than in the
PST-AD arm (21%) had missed appointments in the prior
3 months. This was not statistically significant
(p = 0.266).
Viral Load and CD4
We found considerable limitations in feasibility of using
the clinic record system to determine HIV viral load
quantification and CD4 T cell counts at baseline and fol-
low-up. For viral load, this was due to (i) the long period
between having blood taken and result being available on
the record system (mean 101 days delay at baseline and
130 days delay at follow-up), (ii) errors in dates (e.g.
mixing up date of blood taken with date result entered),
(iii) timing of blood tests (for instance, within 1 month of
the intervention which would be too soon to expect a
change in viral suppression), (iv) non-random testing i.e.
those with a lower previous viral load were less likely to
have a follow-up test. Viral load data were missing for
12/32 participants (38%). At baseline, one intervention arm
participant and one in the EUC arm were virally sup-
pressed. At follow up 9/12 (75%) in the PST-AD arm
compared to 4/8 (50%) in the EUC arm achieved viral
suppression, but the result was not statistically significant
(p = 0.356). On CD4 count outcomes, most participants
lacked data due to the rarity of follow-up CD4 being
requested.
Self-Report Adherence
The proportion of participants who self-reported missing a
dose in the past 4 weeks decreased for both arms. In the
intervention arm this fell from 21 to 8% and in the EUC
arm from 22 to 7% (Table 3). There was no difference
between arms at follow-up (p = 0.722).
Electronically-Measured Adherence
We collected an adherence score for 30/32 participants
(94%) at baseline and 25/28 (89%) at follow-up. Missing
data was due to low battery in the device (needing
Table 2 Characteristics of participants at baseline
Intervention arm (N = 14) Enhanced usual care arm
(N = 18)
Total (N = 32)
N (%) Median (IQR) N (%) Median (IQR) N (%) Median (IQR)
Age (years) 41.8 (33.7–45.3) 35.8 (24.1–40.6) 37.8 (24.6–44.9)
Gender: female 9 (64.3) 12 (66.7) 21 (65.6)
Marital status
Married 7 (50.0) 9 (50.0) 16 (50.0)
Single 5 (35.7) 7 (38.9) 12 (37.5)
Widowed 2 (14.3) 2 (11.1) 4 (12.5)
Highest education
Pre-primary and primary school 4 (28.6) 5 (27.7) 9 (28.1)
Secondary and high school 9 (64.3) 9 (50.0) 18 (56.3)
Tertiary 1 (7.1) 4 (22.2) 5 (15.6)
Employment status
Not employed 8 (57.1) 5 (27.8) 13 (40.6)
Employed (full-time, part-time and self-employed) 6 (42.9) 12 (66.6) 18 (56.3)
Student 0 1 (5.6) 1 (3.1)
Food insecurity: skipped meals in the last month 3 (21.4) 3 (16.7) 6 (18.8)
Time on ART (years) 5.5 (2.3–7.6) 3.9 (3.0–6.4) 4.3 (2.9–6.5)
ART regimen
First line 12 (85.7) 14 (77.8) 26 (81.3)
Second line 2 (14.3) 4 (22.2) 6 (18.7)
Viral load non-suppressed ([200 copies/ml) 13 (92.9) 17 (94.4) 30 (93.8)
CD4 count (cells/mm3) 300 (144–403) 325 (140–561) 316 (142–438)
AUDIT-C alcohol screen 0 2 (11.1) 2 (6.3)
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charging), network problems, or expiry of cell phone
credit. In one case the participant said the Wisepill had
been stolen. As shown in Table 3, the percentage of par-
ticipants with good adherence (C90% of pills taken on
time) increased for both groups although there was no
statistically significant difference between arms at follow-
up (p = 0.190). In the intervention arm there was a greater
absolute increase in good adherence (25%) than in the EUC
arm (14%). Mean adherence also increased for both arms.
At an individual level, mean change in the intervention arm
was 11.2 (95% CI 0.6, 21.9) and in the EUC arm was 11.6
(95% CI -2.1, 25.3). A linear regression model found no
association between arm and adherence score at follow-up,
controlling for baseline adherence score (coefficient = 2.6,
95% CI -11.2, 16.5, p = 0.695, N = 24, 21 residual
degrees of freedom, F = 7.76, adjusted R2 = 37%).
Stepped Care in the Intervention Arm
Thirty-six percent (5/14) of participants were ‘stepped up’
to be seen by the psychologist at session 4. During exit
interviews, the ADC said in most of the cases, by session 3,
she had been aware that she was going to need to refer the
participant to the psychologist, because she was struggling
to assist the participant to generate solutions. Two of these
14 (14%) were then further referred to Step 3 for an
antidepressant.
Experience of Participating in a Pilot Randomised
Controlled Trial
We conducted 35 exit interviews, 27 with participants (12
PST-AD arm, 15 EUC arm) and six with ADCs (two
trained in PST-AD and four trained in EUC but not in PST-
AD). Key themes that emerged were the acceptability and
perceived benefits of the PST-AD intervention, the sense of
being ‘‘helped’’ by the electronic medication event moni-
toring, and the contamination that occurred in the EUC
arm.
Acceptability of the Intervention (See Table 4)
Interviews with intervention arm participants notably
revealed high levels of acceptability and perceived benefits
of the intervention with many participants saying that the
intervention was ‘‘great’’ and that the intervention ‘‘should
help everyone because this is extremely beneficial’’. Par-
ticipants noted that it had ‘‘educated’’ them about adherence
and also about depression. Participants could now identify
why adherence is necessary: ‘‘If I do not adhere it means that
the viral load will rise and in turn will affect my health’’,
understand terminology commonly used by health care
professionals: ‘‘I benefitted a lot from all the sessions—I did
not understand the difference between viral load and CD4
but through the sessions now I know the difference’’, and
Table 3 Clinical Outcomes
Intervention arm EUC arm
Baseline
(n = 14)
Follow-up
(n = 14)
Baseline
(n = 18)
Follow-up
(n = 18)
Viral suppression 1 (7.1%) 9 (75%)b 1 (5.6%) 4 (50%)c
Switched to 2nd or 3rd line regimen 6 (42.9%) 7 (38.9%)
Missed at least one HIV care appointment in last 3 months: N
(%)
4 (28.6%) 3 (21.4%) 4 (22.2%) 8 (44.4%)
Number of missed HIV care appointment in last 3 months: mean
(SD)
0.36 (0.63) 0.29 (0.61) 0.39 (0.78) 0.72 (0.96)
Baseline
(n = 14)
Follow-up
(n = 13)
Baseline (n = 18) Follow-up
(n = 15)
Depression Shona Symptom Questionnaire Score: mean
(SD)
8.5 (1.9) 3.8 (3.3) 9.3 (1.2) 5.5 (2.7)
Patient Health Questionnaire score: mean(SD) 13.8 (2.2) 3.1 (3.1) 9.2 (3.3) 5.7 (3.9)
Self-report missed dose(s) within last month: N (%) 3 (21.4%) 1 (7.7%) 4 (22.2%) 1 (6.7%)
Electronically-measured adherence C90%: N (%) 8 (57.1%) 9 (81.8%)b 7 (43.8%)b 8 (57.1%)a
Electronically-measured adherence: mean (SD) 85.3 (20.8) 93.8 (10.2)b 71.4 (30.6)b 85.3 (26.2)a
a missing data on 1 participant
b missing data on 2 participants
c missing data on 10 participants
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Table 4 Key themes from qualitative interview
Theme Quote
Acceptability and benefits of the intervention
(Interviews with intervention arm participants)
‘‘The project should continue educating me on how to take my medications and to deal with
my memory loss’’
‘‘They should help everyone because this is extremely beneficial’’
‘‘Tendai should consider educating more people on depression and adherence’’
‘‘I learnt the importance of adherence—if I do not adhere it means that the viral load will
rise and in turn will affect my health’’
‘‘I benefitted a lot from all the sessions I did not understand the difference between viral
load and CD4 but through the sessions now I know the difference. I can now manage to
solve my problems on my own’’
‘‘I am now make use of reminders for myself, such as stickers and alarms so that I will be
able to take my pills on time and I am now getting condoms from a clinic’’
‘‘I have learnt that I can do something with the little I have and become someone … I am
translating for other people especially in church and I am saving out of it’’
‘‘With the help of the counsellor, I managed to come up with a solution to my financial
problem. I have now started my own business of selling food’’
Acceptability and benefits of the intervention
(Interviews with ADCs and staff)
Client-centred focus
Continuity of care
Incentives for participants
‘‘The use of video makes clients remember to take their drugs on time for it explains about
the replication of the virus which leads to drug resistance…So clients have a better
understanding of how ART works and what to do to remain healthy. The use of stickers
also helps clients to remember taking their drugs on time’’
‘‘I think Nzira Itsva should definitively be implemented instead of standard care. We have
all learnt a lot, and we have seen that the patients have benefitted’’
‘‘I think it should definitively be used in all hospitals. Absolutely’’
‘‘It has been a great benefit to our patients. Particularly the problem-solving component. It
addresses some of the psychological and psychosocial factors affecting adherence. The
introduction of screening for depression that came with the new intervention also had a
positive impact on the way counselling is being conducted, with patients with depression
being picked u.’’
‘‘In Nzira Itsva clients open-up a lot. For example when you ask a patient where they store
their medications, they will end up saying there is stigma, which leads them to put their
drugs under the bed…they stay with their relatives, which make it difficult. So you then
know that these are the major problems… and so together we can then think about how to
address these challenge.’’
‘‘Basically, the clients could take the lead in decision making and coming up with solutions
to their problems, I was only there to guide them. So you see this is what I liked about
New Direction. And I know the clients find it very helpful’’
‘‘It is different to standard care in that the client controls the sessions. In standard care, the
client is not given the chance to think… it’s like spoon feeding. But with Nzira Itsva, it is
the client who will be in control and this helps them to empower themselves and think for
themselves’’
‘‘There is continuity with the same counsellor and this means the client will have a good
rapport with the counsellor, and opens up with everything, which leads to good
adherence… You really get to know the client, and so you learn the root cause of poor
adherence’’
‘‘I liked the fact that the clients really opened-up, and you see it’s because you were doing a
follow up. It’s like that with Nzira Itsva—when you see a client the 1st time you don’t
just leave them but they will come for more sessions. This is unlike standard care where
we just see the client once, and then after that they will see a different person…So it is
really good for monitoring the adherence’’
‘‘The good thing about these sessions is continuity…that you have a number of sessions
and don’t shift counsellors. I think this is very helpful because you will then be able to get
a better understanding of the client’s problems. If the client keeps seeing different
counsellors, it is not good as none of the counsellors will have a good understanding of
the client’s problems’’
‘‘The idea of giving clients incentives is very acceptable to clients and reduces the issue of
missed appointments… the client will know that whenever I go for the sessions I will get
the bus fare and when I am hungry or thirsty I will get refreshments’’
‘‘Many clients at our clinic are failing to come due to financial problems’’
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start incorporating reminders into their daily routine: ‘‘I now
make use of reminders for myself, such as stickers and
alarms so that I will be able to take my pills on time’’.
Participants stated the intervention ‘‘should be continued’’
in particular it ‘‘should consider educating more people on
depression and adherence’’. Ninety-one percent (11/12) of
intervention arm participants felt that the counselling ses-
sions had influenced the way in which they take their
medication, with 75% (9/12) stating that they were now able
to take their pills on time. This compared to 47% (7/15) of
the EUC participants. The animation helped the clients to
see why taking medication on time was so important,
motivating them to problem-solve around their barriers to
adherence so they could follow what the counsellors and the
doctors asked them to do. Many participants in the inter-
vention arm and some in the EUC arm said that the impact of
the intervention included learning how to, for example,
problem-solve, manage stress, generate forms of employ-
ment, deal with familial problems and lead a healthier
lifestyle. Some intervention arm participants said that
through talking about their financial difficulties with the
counsellor, they have ‘‘started their own business now’’,
‘‘found employment’’ or ‘‘begun a project’’. One participant
noted, ‘‘I have learnt that I can do something with the little I
have and become someone. In my case I am able to translate
English into French and Lingala, I am translating for other
people especially in church and I am saving out of it’’. The
guidance and support of the ADCs helped participants
develop ways to manage their financial difficulties: ‘‘With
the help of the counsellor, I managed to come up with a
solution to my financial problem. I have now started my own
business of selling food.’’ Perceptions amongst participants
appear to be shared by the counsellors with experience of the
PST-AD intervention. ADCs highlighted how the inter-
vention ‘‘improves adherence’’, ‘‘helps clients understand
better the impact of adherence’’, ‘‘shows them why they
need to take their pills’’ and ‘‘empowers them on how to
solve their own problems’’. As one counsellor highlighted:
‘‘The use of video makes clients remember to take their
drugs on time for it explains about the replication of the
virus which leads to drug resistance…So clients have a
better understanding of how ART works and what to do to
remain healthy. The use of stickers also helps clients to
remember taking their drugs on time.’’ They spoke about the
‘‘client-centred’’ or ‘‘patient-driven’’ quality of the inter-
vention, and how this helped the client to ‘‘open up about
barriers to adherence’’, helped them to ‘‘connect with cli-
ents’’ and that clients ‘‘seem to respond well to being the
driving force’’. As one ADC explained, ‘‘Basically, the
clients could take the lead in decision making and coming up
with solutions to their problems, I was only there to guide
them. So you see this is what I liked about New Direction.
And I know the clients find it very helpful’’. Another ADC
specifically compared it to standard care and stated why they
thought the intervention was better for their clients: ‘‘It is
different to standard care in that the client controls the
sessions. In standard care, the client is not given the chance
to think on their own. Basically, it’s like spoon feeding. But
with New Direction, it is the client who will be in control
and this helps them to empower themselves and think for
themselves’’. ADCs in both arms of the study liked that
sessions were delivered by the same counsellor, which they
reported built client-counsellor trust. ADC’s felt this helped
lead to ‘‘good adherence’’ because: ‘‘There is continuity
with the same counsellor and this means the client will have
a good rapport with the counsellor, and opens up with
everything, which leads to good adherence…You really get
to know the client, and so you learn the root cause of poor
adherence’’. Again the ADCs compared this with standard
care and stated this was an improvement: ‘‘I liked the fact
that the clients really opened-up, and you see it’s because
you were doing a follow up. It’s like that with New Direc-
tion—when you see a client the first time you don’t just
leave them but they will come for more sessions. This is
unlike standard care where we just see the client once, and
then after that they will see a different person…So it is really
good for monitoring the adherence’’. ADCs explained that
many clients face considerable financial difficulties, and
Table 4 continued
Theme Quote
Potential intervention contamination (Interviews
with EUC counsellors)
‘‘It was wonderful working with the clients who were on the Tendai study. Every time they
came to me I knew exactly what to do. I had to concentrate on adherence issues. Because
they were on the Tendai study I gave them more attention and time than I usually do with
my other clients. That helped a lot because I was able to understand why they had
adherence problems and was able to help them which we hardly do with the other clients’’
‘‘I knew that people in the Tendai Study had depression so I took my time to focus on the
problems that were causing them stress and we did stress management’’
‘‘I gave them more time to talk because of the sensitivity of depression which we do not
normally do and being able to air their views helped me understand their problems better
and was able to help’’
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thus providing small research incentives of bus fare and
refreshments facilitated a high uptake of care. One ADC
explained ‘‘The idea of giving clients incentives is very
acceptable to clients and reduces the issue of missed
appointments. I mean the bus fare motivates the client to
come for the sessions. The client will know that whenever I
go for the sessions I will get the bus fare and when I am
hungry or thirsty I will get refreshments. Many clients at our
clinic are failing to come due to financial problems’’. The
ADCs and the two senior clinic staff felt that the PST-AD
intervention should be continued and scaled-up as long as
human resources were adequate, as the extra sessions were
not part of standard care.
Experience of Electronic Adherence Monitoring
Responses suggested that the Wisepill had an effect on
participants’ medication behaviour. Common comments
included, ‘‘it helped me a lot’’, ‘‘it was very helpful’’, ‘‘it had
a positive effect’’ and ‘‘with the Wisepill I managed to take
my pills very well. I was taking them on time’’. Indeed, 50%
of the EUC participants stated that it aided them in taking
their pills on time, while 75% declared that they were more
likely to take their medication when using the Wisepill than
without it. Several participants in both arms said that the
device gave them a sense of ‘‘feeling monitored’’.
Contamination Risks of conducting a Trial in One Clinic
Interviews with the four counsellors who had delivered the
EUC arm revealed that their awareness of the study may
have impacted significantly on the way in which they
treated the EUC participants and conducted the counselling
sessions with them. Although the EUC counsellors were
asked not to do anything differently other than to provide
additional sessions of usual care, it emerged from the
interviews that, as they were aware that the participants in
the intervention arm of the Tendai study were improving,
and had heard of the problem-solving approach ‘‘through
the cubicle curtains’’, they were motivated to help their
patients produce similar positive results. For example, one
counsellor explained that, because she had some under-
standing of what the study was about, she ‘‘knew exactly
what to do’’ and felt she should ‘‘give those patients more
attention and time than I usually do with my other clients.’’
Similarly, another counsellor indicated that he ‘‘was aware
that any patient coming through Tendai would have
depression’’ and thus ‘‘did not concentrate on nutrition and
other issues as their problems were mental issues’’, while
another said she now knows that ‘‘if you pay more attention
to the patient and give them more time to talk about their
problems the outcomes of adherence would improve’’.
Indeed, all four counsellors stated that they gave the study
participants a lot more time and information, in comparison
with their other patients. As one counsellor put it, ‘‘I was
more caring with the Tendai patients’’.
Further contamination was revealed through interview-
ing the ADC who delivered the PST-AD intervention. It
emerged she had given two sessions of PST-AD to one
EUC arm participant and one session each to 6 EUC arm
participants because EUC counsellors referred these clients
to her after their EUC sessions due to concerns about the
participants’ psychosocial issues.
Discussion
This is the first study to show the feasibility and accept-
ability of a model of care to enhance adherence and treat
depression in a low-income country in SSA. This model
involved task-sharing and stepped care, with trained and
supervised adherence counsellors providing six sessions of
PST for both adherence and depression, with options
embedded to refer to a specialist based on follow-up out-
come measures. We have provided evidence of the
acceptability of the intervention to both participants and
adherence counsellors, and of high fidelity to delivering the
intervention at least for initial sessions of therapy. In
preparation for a future trial, we have shown feasibility of
recruitment, participant randomisation and retention.
Although it is relatively common that time-matched con-
trols are not used in effectiveness trials, one limitation was
that the study was not a time-matched RCT, having six
sessions in the PST-AD arm and three in the EUC arm.
In terms of acceptability, both clients and ADCs
appreciated especially the collaborative style of the PST-
AD intervention, which put the client ‘‘in the driving seat’’
of their adherence and trained them how to problem-solve
for themselves. This is an important finding which fits with
evidence from the US on the use of PST for adherence [7]
but differs from the standard didactic way of delivering
information which is common in HIV clinics in Zimbabwe,
and from interventions relying simply on education or
reminders [50].
Challenges discovered during the study included the
difficulty in relying on routinely collected data to pick up
potentially eligible clients at risk of poor adherence to
ART, due to weakness in the health records system. For a
future trial, recruitment could be enhanced by conducting
research measurement to screen for detectable viral load,
by outreach screening for patients who miss appointments,
and through making use of pharmacy re-fill data as a way
to identify patients late for drug pick up [51].
Another important lesson learned for a future trial was
about checking fidelity to the adherence component of the
follow-up sessions. During the follow-up sessions fidelity to
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PST for depression was very good, but fidelity to PST for
adherence to ART was poor, dropping from 83% in session
1–33% in session 3. For instance, if the individual had
financial constraints making it difficult to afford bus fare to
collect medication, or family disharmony interfering with
achieving a regular medication schedule, the ADC focussed
on the underlying problem, often neglecting to review the
proximal target of actual adherence behaviour. The ADC
also commonly neglected to work on additional barriers to
adherence that had been elicited in the first session. This
may have been due to the fact that ADCs trained initially as
part of our preparatory work were re-located by the hospital
matron to critical areas, especially antenatal adherence
counselling [11]. This resulted in us having to train a new
ADC for the pilot trial, and we may not have sufficiently
emphasised the importance of adherence to ART in the
follow-up booster sessions. We think that the ADC became
engaged with supporting the participants with their depres-
sion (for example helping them problem-solve over poverty-
related and relationship-related stressors) which she found
interesting and rewarding. She felt that these stressors were
underlying the client’s problems with adherence and thus
she elected to focus on them. However, for the future, it will
be important to emphasise that the counsellors should also
continue to attend to the proximal target of adherence
behaviour. For our future trial, we plan to ensure that this is
addressed through training and supervision and with real-
time monitoring of fidelity with interim checking.
Another challenge identified through this feasibility trial
was contamination. A number of EUC participants were
referred into the active intervention and had one or two
sessions of PST for depression prior to outcome assess-
ment. Furthermore, the extra sessions freely offered as part
of EUC may have helped explain some improvement in the
depression and/or adherence levels of the control patients.
In addition, adherence counsellors in the EUC arm revealed
they had tried to copy what they had heard being delivered
in the PST-AD cubicles. This was largely motivated by
their wish to learn more, and by pride at developing new
skills especially if these can lead to professional certifi-
cates. Copying what they could hear being delivered in the
intervention arm was facilitated by the lack of privacy. The
counselling areas are divided only by curtains. We think
our finding is impressive that depression improved signif-
icantly more in the PST-AD arm, even in the face of this
contamination. For a future trial we will limit contamina-
tion risks through having an ADC dedicated to delivering
the intervention arm who does not provide routine care,
and using a separate private room or cabin. An alternative
would be to have some form of placebo control, to allow
ADCs in the control arm to gain skills and feel included.
Another option would be a cluster design, with clinics
being the unit of randomisation.
We demonstrated strong acceptability of the PST-AD
intervention through high attendance and through exit
interviews. This, combined with evidence from high
income countries of the efficacy of combined treatment of
depression and adherence using CBT [24–26], provides
solid justification for a trial of PST-AD in this low-resource
setting where nearly 15% of the population are infected
with HIV. PST, although often used as part of CBT, takes
its theoretical base from social problem-solving and is an
evidence-based treatment for depression that is thought to
work through enabling a more positive orientation towards
problems and improving coping skills [52, 53].
The very small sample size lead this study to be
underpowered, and there may have been missed effects.
There were many instances in which there were differences
between the PST-AD arm and the EUC arm, e.g. in levels
of ART adherence, HIV appointment adherence, and viral
suppression, which did not achieve statistical significance,
and in future large trial, these differences may emerge as
significant. We used electronic monitoring of adherence for
the current study, which is considered a robust measure.
However, it is expensive and may distort adherence
behaviour [54], especially if used as we did only for short
periods [55]. An alternative measure of adherence could be
Pharmacy Refill Percentage and Appointment Adherence.
A future trial could include on-going viral suppression as a
primary outcome of interest. Other questions that could be
explored through a future, larger trial could be whether
‘stepping up’ mediates any of the improved outcomes, and
whether baseline severity moderates outcomes.
Current multidisciplinary guidelines for mental health-
care (e.g. mhGAP) recommend using a stepped care
approach to depression, but this has not been investigated
previously in PLWH with depression and poor adherence
to ART [56]. A strength of our intervention was deploying
ADCs to provide Step 1 PST for depression, rather than a
nurse or mental health specialist. ADCs are an available
cadre who currently deliver adherence support in most low-
income countries in SSA [57, 58]. We opted for additional
PST by a qualified psychologist for Step 2, but if antide-
pressants were more generally available in HIV care set-
tings in LMIC, and nurses were trained to prescribe this,
this would arguably be more sustainable.
Results from this study inform and justify a future ran-
domised controlled trial of task-shifted PST-AD. If an
adequately powered trial mirrors efficacy in enhancing
adherence, reducing depression and missed HIV care
appointments, and improving HIV viral suppression, this
task-shifting model has the potential to be scaled up within
existing SSA health care systems. The intervention could
have a great impact on the lives of many people living with
the dual challenges of HIV and clinical depression in low-
resource settings.
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